FY2025 · ended Dec 31, 2025 · Revenue $407.32M, +22.1% YoY · Filed Feb 19, 2026
Ardelyx, Inc. (ARDX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $407.3 million and a net loss of $61.6 million. Free cash flow was -$44.0 million. As of Sep 30, 2026 it held $285.3 million in cash and investments and $256.3 million in total debt.
Revenue (TTM)
$468.22M
+17.6% vs year-ago TTM
Net income (TTM)
$-55.47M
+1.9% vs year-ago TTM
Operating cash flow (TTM)
$-15.51M
+71.1% vs year-ago TTM
Free cash flow (TTM)
$-15.96M
+71.2% vs year-ago TTM
EPS (TTM)
$-0.22
+4.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
245.25M
+2.9% vs prior year
Net cash
$29.00M
as of Sep 30, 2026
Operating margin
-7.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fremont, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1437402
- Former names
- NTERYX INC (until Jun 9, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $407.3M | $333.6M | $124.5M | $52.2M | $10.1M |
| Operating income | -$41.0M | -$27.9M | -$63.3M | -$63.8M | -$154.3M |
| Net income | -$61.6M | -$39.1M | -$66.1M | -$67.2M | -$158.2M |
| Diluted EPS | -$0.26 | -$0.17 | -$0.30 | -$0.42 | -$1.52 |
| Operating cash flow | -$42.5M | -$44.8M | -$89.7M | -$70.0M | -$152.6M |
| Free cash flow | -$44.0M | -$45.8M | -$90.1M | -$70.1M | -$154.4M |
| Total assets | $501.6M | $435.8M | $297.6M | $190.1M | $149.9M |
| Total liabilities | $334.7M | $262.5M | $130.8M | $91.7M | $67.3M |
| Stockholders' equity | $166.9M | $173.3M | $166.8M | $98.3M | $82.6M |
| Cash and investments | $264.7M | $250.1M | $184.3M | $123.9M | $116.7M |
| Total debt | $208.0M | $153.4M | $56.0M | $36.5M | $45.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Aug 17, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
New debt
|
Jul 2, 2026 | Jun 29, 2026 |
All 1006 Ardelyx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.